Akero Therapeutics, Inc.
AKRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | -11.61 | 28.34 | -0.50 |
| FCF Yield | -12.32% | -11.84% | -4.33% | -10.82% |
| EV / EBITDA | -5.48 | -6.86 | -17.09 | -5.85 |
| Quality | ||||
| ROIC | -36.29% | -30.78% | -33.14% | -59.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.96 | 0.83 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -58.29% | -57.12% | -16.11% | -12.30% |
| Safety | ||||
| Net Debt / EBITDA | 1.07 | 1.40 | 2.15 | 1.48 |
| Interest Coverage | -61.14 | -55.78 | -155.83 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -183,047.50 | -88,581.72 | -11,185.85 | -10,031.52 |